We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIXC
101
AIxCrypto Holdings Inc
AIXC
$22.7M
$922K 0.01%
22
– –
ABUS icon
102
Arbutus Biopharma
ABUS
$1.03B
$912K 0.01%
180,582
– –
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$726K 0.01%
4,827
– –
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$668K 0.01%
100,000
– –
BDSI
105
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$620K 0.01%
210,021
– –
IMDZ
106
DELISTED
Immune Design Corp.
IMDZ
$581K 0.01%
148,937
– –
TARA icon
107
Protara Therapeutics
TARA
$228M
$567K ﹤0.01%
7,465
– –
FLGT icon
108
Fulgent Genetics
FLGT
$548M
$548K ﹤0.01%
125,000
– –
AFMD
109
DELISTED
Affimed
AFMD
$520K ﹤0.01%
40,000
– –
FPRX
110
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$422K ﹤0.01%
19,247
– –
TTOO
111
DELISTED
T2 Biosystems, Inc
TTOO
$412K ﹤0.01%
20
– –
CCXI
112
DELISTED
ChemoCentryx, Inc.
CCXI
$292K ﹤0.01%
49,064
– –
NVIV
113
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$255K ﹤0.01%
18
-3
-14% -$69.4K
TENX icon
114
Tenax Therapeutics
TENX
$65.5M
$171K ﹤0.01%
11
– –
BGMSP
115
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$92K ﹤0.01%
13,253
– –
BTX.WS
116
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$2K ﹤0.01%
20,084
– –
VYGR icon
117
Voyager Therapeutics
VYGR
$209M
– –
-237,014
Closed -$4.88M
TMBR
118
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-40
Closed -$171K
LOXO
119
DELISTED
Loxo Oncology, Inc
LOXO
– –
-96,062
Closed -$8.85M
DMTX
120
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-1,251,881
Closed -$7.51M
NDRM
121
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-571,667
Closed -$22.2M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2017 Portfolio in Review

As of Q4 2017, Julian Baker held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Julian Baker's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Julian Baker fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Julian Baker's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Julian Baker opened 8 new positions and closed 5 in Q4 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.